Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab + Rituximab in Persistent/Chronic ITP
NCT05338190Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary immune thrombocytopenia (ITP) comparing Belimumab + Rituximab with Placebo + Rituximab (2 arms). Primary endpoint: Overall Response Rate (CR + R) at 52 weeks. Started Nov 2022; status: recruiting.
02
Drugs
belimumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05338190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338190.